ranitidine

(redirected from Ranitidine bismuth citrate)
Also found in: Dictionary, Thesaurus.
Related to Ranitidine bismuth citrate: Pylorid

ranitidine

 [rah-nit´ĭ-dēn]
an antagonist of histamine H2receptors, used as the hydrochloride salt to inhibit stomach hydrochloric acid secretion in treatment of peptic ulcers, gastroesophageal reflux, and conditions of gastric hypersecretion, administered orally, intramuscularly, or intravenously.

ranitidine

(rə-nĭt′ĭ-dēn′)
n.
A histamine receptor antagonist, C13H22N4O3that inhibits gastric acid secretion and is used primarily to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease.

ranitidine

Zantac Therapeutics An H2-receptor antagonist used to treat peptic ulcer disease, gastric and duodenal ulcers, esophageal erosions, GERD, and conditions–eg, Zollinger-Ellison disease and systemic mastocytosis in which there is ↑ H2 activity due to blocking of the binding of histamine to H2 receptors, resulting in ↓ intracellular concentration of cAMP and acid secretion by gastric parietal cells Adverse reactions Diarrhea, headache, fatigue, myalgia, constipation, confusion, agranulocytosis, gynecomastia, impotence, allergic reactions, tachycardia, arrhythmias, interstitial nephritis, etc. See H2 blockers, Histamine receptor antagonists.

ranitidine

An H-2 (histamine-2) receptor antagonist drug used to reduce acid secretion in cases of peptic ulceration. A band name is Zantac. See also RANTITIDINE BISMUTH CITRATE.
References in periodicals archive ?
Seven-day triple therapy of ranitidine bismuth citrate + clarithromycin + metronidazole or amoxicillin For these therapies, a high-quality systematic review of 8 studies reported eradication rates of 81% (95% CI, 77%-84%) with amoxicillin and 88% (95% CI, 85%-90%) with metronidazole.
Ranitidine bismuth citrate (RBC) 400 mg BID + clarithromycin 500 mg TID x 2wks then RBC 400 mg BID x 2 wks
PPI quadruple therapy or a regimen including furazolidone (a monoamine oxidase inhibitor) may serve as second-line treatment for eradication of initial failures and in case of metronidazole resistance.[18,19] Studies using ranitidine bismuth citrate in place of PPIs have also shown comparable results.